Values First Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Values First Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-67,004	Closed	-$118K	–	305
2024 Q3	$118K	Buy	67,004 +4,333	+7%	+$6.05K	0.06%	174
2024 Q2	$73.3K	Buy	62,671 +52,257	+502%	+$131K	0.04%	159
2024 Q1	$94.1K	Sell	10,414 -3,783	-27%	-$36.8K	0.06%	158
2023 Q4	$154K	Buy	14,197 +736	+5%	+$5.52K	0.09%	148
2023 Q3	$108K	Sell	13,461 -2,784	-17%	-$23.2K	0.07%	148
2023 Q2	$176K	Sell	16,245 -2,027	-11%	-$17.4K	0.11%	148
2023 Q1	$126K	Buy	+18,272	New	+$115K	0.08%	156

Other funds holding MRNS

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Values First Advisors's MRNS Position: Q4 2024 in Review

Values First Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 67,004 shares — an estimated $118K sold.

Values First Advisors first reported a position in MRNS in Q1 2023 and held it in 7 quarters. The position peaked at $176K in Q2 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

Values First Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
Values First Advisors sold 67,004 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $118K.
Values First Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q1 2023 and held it in 7 quarters.
Values First Advisors's Marinus Pharmaceuticals, Inc position peaked at $176K in Q2 2023.
53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Values First Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.